Meriofert Set (Luteinising Hormone (Human), Follicle-Stimulating Hormone)

Meriofert Set, containing human luteinising hormone and follicle‑stimulating hormone, is used in reproductive medicine to address hormone‑dependent infertility.

• Ovulation induction: promotes follicular growth and ovulation in women with anovulatory infertility.
• Controlled ovarian hyperstimulation: supports multiple follicle development during in‑vitro fertilisation cycles.
• Male hypogonadotropic hypogonadism: stimulates spermatogenesis in men with deficient gonadotropin production.
• Luteal phase support: enhances corpus luteum function to improve implantation rates in assisted reproduction.

• The preparation provides exogenous human luteinising hormone (LH) and follicle‑stimulating hormone (FSH) that bind to their respective G‑protein‑coupled receptors on ovarian granulosa cells and testicular Sertoli cells. Activation of LH receptors stimulates androgen production and luteinisation, while FSH receptor activation promotes follicular recruitment, growth, and estradiol synthesis, together supporting gametogenesis and steroidogenesis. The combined activity restores the hormonal milieu required for normal follicular development and sperm production.

Adverse reactions to Meriofert Set are reported primarily at the injection site and through systemic hormonal effects.

Common Side Effects

• Injection site pain: mild discomfort or tenderness at the administration site.
• Local erythema: redness around the injection area.
• Headache: transient mild to moderate headache.
• Nausea: occasional feeling of nausea without vomiting.
• Ovarian hyperstimulation symptoms: abdominal bloating and mild pelvic discomfort.
• Fatigue: feeling of tiredness or low energy.

Serious or Rare Side Effects

• Ovarian hyperstimulation syndrome (OHSS): severe abdominal pain, rapid weight gain, and fluid accumulation.
• Thromboembolic events: rare blood clot formation.
• Allergic reaction: rash, itching, or anaphylaxis.
• Severe allergic reaction (anaphylaxis): difficulty breathing, swelling of face or throat.
• Ectopic pregnancy: increased risk in assisted reproduction cycles.
• Sepsis: systemic infection related to injection site.

When using Meriofert Set, clinicians should observe specific precautions to minimise risks and ensure product integrity.

• Indication verification: confirm diagnosis of gonadotropin‑dependent infertility before administration.
• Hormone monitoring: regularly assess serum estradiol and testosterone levels during therapy.
• OHSS risk assessment: evaluate patient history and ovarian response to avoid severe hyperstimulation.
• Contraindications: avoid use in known hypersensitivity to human gonadotropins or active components.
• Pregnancy status: discontinue if pregnancy is confirmed unless specifically indicated.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meriofert Set may interact with other medications that influence hormonal pathways or coagulation.

Major Interactions (Avoid)

• GnRH antagonists: may blunt the intended gonadotropin response.
• Anticoagulants: increased risk of bleeding at injection sites.
• High‑dose estrogen therapy: can alter FSH/LH activity and reduce efficacy.

Moderate Interactions (Monitor Closely)

• Oral contraceptives: may require washout period before initiating therapy.
• Thyroid hormone replacement: monitor thyroid function as gonadotropins can affect metabolism.
• Steroid hormones: adjust dosing if concurrent anabolic or corticosteroid therapy is used.